Current Environment: Production

Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Conditions

Duchenne Muscular Dystrophy

Recruitment Status

TERMINATED

Eligibility Criteria

Inclusion Criteria:

* Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
* Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.

Intervention

Intervention Type

Intervention Name

DRUG

Casimersen

DRUG

Golodirsen

Phase

PHASE3

Gender

MALE

Min Age

7 Years

Max Age

23 Years

Download Date

2024-09-19

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy NCT03532542

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services